ITK and hematopoietic and lymphoid cell neoplasm: There is credible evidence to confirm the good curative effect of ibrutinib in patients with malignant hematologic neoplasm, whereas it seems to have no significant effect in several solid tumors, including BC (28, 29), which is highly consistent with our result that higher ITK expression leads to longer OS time (p = 0.009).